News for Innoviva, Inc. (INVA)

Summary Innoviva Inc (INVA), a diversified holding company with a focus on royalties and healthcare investments, announced that its CEO, Pavel Raifeld, will par

Robust royalty portfolio with strong partnerships and innovative healthcare assets.Expansion into critical care and infectious disease markets through strategi

On February 26, 2025, Innoviva Inc (INVA) released its 8-K filing, detailing its financial results for the fourth quarter and full year 2024. Innoviva Inc, a di

Innoviva Inc (INVA), a diversified holding company with a focus on royalties and healthcare investments, announced its financial results for the fourth quarter

Innoviva, Inc. (NASDAQ: INVA) (”œInnoviva” or the ”œCompany”), a diversified holding company with a core royalties portfolio, a leading critical care and

Innoviva's shift to specialty therapeutics is backed by strong financials and a robust pipeline. Read why INVA stock presents an asymmetric risk-reward profile.

On December 31, 2024, Franklin Resources Inc, a prominent investment firm, executed a significant transaction involving Innoviva Inc (INVA). The firm reduced it

ImaginAb, Inc. Innovative Biologics Technology platform acquired by Telix to enable Next-Generation Therapeutic Assets discovery

The major U.S. index futures are currently pointing to a higher open on Monday, with stocks likely to see initial strength following the lackluster performance seen during last Friday's session.

ZeroHedge - On a long enough timeline, the survival rate for everyone drops to zero

Innoviva Inc (INVA), through its subsidiary Innoviva Specialty Therapeutics, Inc. (IST), has announced an exclusive distribution and license agreement with Basi

Innoviva Specialty Therapeutics, Inc., (”œIST”) a subsidiary of Innoviva, Inc. (Nasdaq: INVA), today announced it has entered into an exclusive distribution

**media[493017]**

Innoviva, Inc. (NASDAQ: INVA) (”œInnoviva” or the ”œCompany”), a diversified holding company with a core royalties portfolio, a leading critical care and

SHANGHAI, Nov. 22, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, 'Everest', or the 'Company'), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that data on its critical-care, anti-infective product, eravacycline (XERAVA®), was recently presented in Los Angeles, California at IDWeek 2024. Among the findings, two in vitro study results further demonstrated the broad and consistent antimicrobial activity of eravacycline.

Zai Lab (”œZai Lab”, NASDAQ: ZLAB; HKEX: 9688) and Pfizer (”œPfizer”, NYSE: PFE) announced today a strategic collaboration for the novel antibacterial dr

Innoviva to Participate in the UBS Global Healthcare Conference

Read the latest healthcare industry dashboard see which 10 healthcare stocks are cheaper than their peers in August.

Zai Lab and Innoviva Specialty Therapeutics Announce NMPA Approval for XACDURO ® (Sulbactam-Durlobactam or SUL-DUR) for Hospital-Acquired and Ventilator-Associated Pneumonia Caused by Acinetobacter Ba